{"id":"clm_9B3045B3D04C","entity":"abbott-laboratories","predicate":"total_equity","value":"33,562,000,000 United States dollar","value_json":{"fp":"Q1","fy":2021,"accn":"0001104659-21-061693","form":"10-Q","filed":"2021-05-05","period":"Q1 FY2021","concept":"us-gaap:StockholdersEquity"},"valid_from":"2021-03-31","valid_to":"2021-06-30","published":"2021-05-05","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Abbott Laboratories total equity: 33,562,000,000 United States dollar\", as of 2021-03-31 (until 2021-06-30). Claim clm_9B3045B3D04C, https://asof.is/claim/clm_9B3045B3D04C, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1800/000110465921061693/0001104659-21-061693-index.htm.","url":"https://asof.is/claim/clm_9B3045B3D04C","accessed":"2026-11-09"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_0E0ED6C2D2F1","supersedes":["clm_E91F357595A5"],"first_seen_at":"2026-11-08T16:56:09.404533+00:00","updated_at":"2026-11-08T16:56:16.878388+00:00","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/1800/000110465921061693/0001104659-21-061693-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q1 FY2021","published_at":"2021-05-05T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:StockholdersEquity in 10-Q Q1 FY2021, filed 2021-05-05"},"legend":{"dates":"valid_from: when the claim took effect (a period figure: the day its period closed). published: the earliest day a source on the record published it (a filing's filing date, a post's date; null when no source carries one). recorded: the day AsOf first held it. A figure can take effect weeks before it is published.","citation":"citation: how to cite the row (plain: one sentence with the value, its as-of date, the claim id and URL, the day answered and the primary source; url: the claim page; accessed: the day answered). APA and BibTeX forms are on the claim page.","why_not":{},"checked_by":{"sec-filing":"parsed from the SEC filing"}}}